Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  HIV Infection

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 179 articles:
HTML format
Text format



Single Articles


    November 2017
  1. YEN YF, Lan YC, Huang CT, Jen IA, et al
    Human Immunodeficiency Virus Infection Increases the Risk of Incident Autoimmune Hemolytic Anemia: A Population-Based Cohort Study in Taiwan.
    J Infect Dis. 2017;216:1000-1007.
    PubMed     Text format     Abstract available


  2. HUANG YA, Tao G, Samandari T, Hoover KW, et al
    Laboratory Testing of a Cohort of Commercially Insured Users of HIV Preexposure Prophylaxis in the United States, 2011-2015.
    J Infect Dis. 2017 Nov 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  3. STEBA GS, Koekkoek SM, Vanhommerig JW, Brinkman K, et al
    DC-SIGN Polymorphisms Associated with Risk of Hepatitis C Virus Infection Among Men who Have Sex with Men but not Among Injecting Drug Users.
    J Infect Dis. 2017 Nov 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  4. REID MJA, Goosby E
    Patient-Centered Tuberculosis Programs Are Necessary to End the Epidemic.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  5. NAIDOO P, Theron G, Rangaka MX, Chihota VN, et al
    The South African Tuberculosis Care Cascade: Estimated Losses and Methodological Challenges.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  6. CHURCHYARD G, Kim P, Shah NS, Rustomjee R, et al
    What We Know About Tuberculosis Transmission: An Overview.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  7. MATHEMA B, Andrews JR, Cohen T, Borgdorff MW, et al
    Drivers of Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  8. AULD SC, Kasmar AG, Dowdy DW, Mathema B, et al
    Research Roadmap for Tuberculosis Transmission Science: Where Do We Go From Here and How Will We Know When We're There?
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  9. SHAH NS, Kim P, Kana BD, Rustomjee R, et al
    Getting to Zero New Tuberculosis Infections: Insights From the National Institutes of Health/US Centers for Disease Control and Prevention/Bill & Melinda Gates Foundation Workshop on Research Needs for Halting Tuberculosis Transmission.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  10. NEWTON R, Labo N, Wakeham K, Miley W, et al
    Kaposi's sarcoma associated herpesvirus in a rural Ugandan cohort: 1992-2008.
    J Infect Dis. 2017 Nov 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    October 2017
  11. VAN ZOEST RA, Underwood J, De Francesco D, Sabin CA, et al
    Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers.
    J Infect Dis. 2017 Oct 24. doi: 10.1093.
    PubMed     Text format     Abstract available


  12. SIBERRY GK, Amzel A, Ramos A, Rivadeneira ED, et al
    Impact of Human Immunodeficiency Virus Drug Resistance on Treatment of Human Immunodeficiency Virus Infection in Children in Low- and Middle-Income Countries.
    J Infect Dis. 2017 Oct 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  13. KIRKEGAARD-KLITBO DM, Langkilde A, Mejer N, Andersen O, et al
    Soluble Urokinase Plasminogen Activator Receptor Is a Predictor of Incident Non-AIDS Comorbidity and All-Cause Mortality in Human Immunodeficiency Virus Type 1 Infection.
    J Infect Dis. 2017;216:819-823.
    PubMed     Text format     Abstract available


  14. LI G, Nunoya JI, Cheng L, Reszka-Blanco N, et al
    Regulatory T Cells Contribute to HIV-1 Reservoir Persistence in CD4 T Cells Through cAMP-Dependent Mechanisms in Humanized Mice In Vivo.
    J Infect Dis. 2017 Oct 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  15. BERTAGNOLIO S, Beanland RL, Jordan MR, Doherty M, et al
    The World Health Organization's Response to Emerging Human Immunodeficiency Virus Drug Resistance and a Call for Global Action.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  16. DUARTE HA, Panpradist N, Beck IA, Lutz B, et al
    Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 13. doi: 10.1093.
    PubMed     Text format     Abstract available


  17. PINTYE J, Baeten JM, Celum C, Mugo N, et al
    Maternal tenofovir disoproxil fumarate use during pregnancy is not associated with adverse perinatal outcomes among HIV-infected East African women: a prospective study.
    J Infect Dis. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  18. SILVERMAN RA, Beck IA, Kiptinness C, Levine M, et al
    Prevalence of Pre-antiretroviral Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-infected Individuals Initiating Therapy in Kenya, 2013-2014.
    J Infect Dis. 2017 Oct 10. doi: 10.1093.
    PubMed     Text format     Abstract available


  19. ROH ME, Shiboski S, Natureeba P, Kakuru A, et al
    Protective effect of indoor residual spraying of insecticide on preterm birth among pregnant women with HIV in Uganda: A secondary data analysis.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  20. MINIOR T, Douglas M, Edgil D, Srivastava M, et al
    The Critical Role of Supply Chains in Preventing Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Settings.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  21. ZHUKOVA A, Cutino-Moguel T, Gascuel O, Pillay D, et al
    The Role of Phylogenetics as a Tool to Predict the Spread of Resistance.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  22. SINGH D, Dhummakupt A, Siems L, Persaud D, et al
    Alternative Sample Types for HIV-1 Antiretroviral Drug Resistance Testing.
    J Infect Dis. 2017 Oct 6. doi: 10.1093.
    PubMed     Text format     Abstract available


  23. PARASKEVIS D
    Investigation of Human Immunodeficiency Virus Outbreaks Among People Who Inject Drugs: Timely Diagnosis and Molecular Surveillance are Crucial.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format    


  24. CHUN HM, Obeng-Aduasare YF, Broyles LN, Ellenberger D, et al
    Expansion of Viral Load Testing and the Potential Impact on Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  25. BUNJUN R, Riou C, Soares AP, Thawer N, et al
    Effect of HIV on the frequency and number of Mycobacterium tuberculosis-specific CD4+ T cells in blood and the airways in latent tuberculosis infection.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  26. CAMPBELL EM, Jia H, Shankar A, Hanson D, et al
    Detailed Transmission Network Analysis of a Large Opiate-Driven Outbreak of HIV Infection in the United States.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


  27. DONAHUE CARLSON R, Sheth AN, Read TD, Frisch MB, et al
    The Female Genital Tract Microbiome Is Associated With Vaginal Antiretroviral Drug Concentrations in Human Immunodeficiency Virus-Infected Women on Antiretroviral Therapy.
    J Infect Dis. 2017 Oct 5. doi: 10.1093.
    PubMed     Text format     Abstract available


    September 2017
  28. BORRE ED, Hyle EP, Paltiel AD, Neilan AM, et al
    The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States.
    J Infect Dis. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format     Abstract available


  29. ADIMORA AA
    Implementing National HIV/AIDS Strategy 2015 Treatment Targets Is Cost-effective and Would Save Lives: What Other Evidence Do We Need?
    J Infect Dis. 2017 Sep 28. doi: 10.1093.
    PubMed     Text format    


  30. PRENDERGAST AJ, Chasekwa B, Rukobo S, Govha M, et al
    Intestinal Damage and Inflammatory Biomarkers in Human Immunodeficiency Virus (HIV)-Exposed and HIV-Infected Zimbabwean Infants.
    J Infect Dis. 2017;216:651-661.
    PubMed     Text format     Abstract available


  31. FOLDI J, Kozhaya L, McCarty B, Mwamzuka M, et al
    HIV-Infected Children Have Elevated Levels of PD-1+ Memory CD4 T Cells With Low Proliferative Capacity and High Inflammatory Cytokine Effector Functions.
    J Infect Dis. 2017;216:641-650.
    PubMed     Text format     Abstract available


  32. ROCKWOOD N, Sirgel F, Streicher E, Warren R, et al
    Low Frequency of Acquired Isoniazid and Rifampicin Resistance in Rifampicin-Susceptible Pulmonary Tuberculosis in a Setting of High HIV-1 Infection and Tuberculosis Coprevalence.
    J Infect Dis. 2017;216:632-640.
    PubMed     Text format     Abstract available


  33. KOOIJ KW, Vogt L, Wit FWNM, van der Valk M, et al
    Higher Prevalence and Faster Progression of Chronic Kidney Disease in Human Immunodeficiency Virus-Infected Middle-Aged Individuals Compared With Human Immunodeficiency Virus-Uninfected Controls.
    J Infect Dis. 2017;216:622-631.
    PubMed     Text format     Abstract available


  34. MOORE T, Dembry LM, Saag MS
    Sunday in the Park with Infectious Disease: Workforce Mismatch in a Colorful Universe of Possibilities.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  35. GALLANT JE
    Human Immunodeficiency Virus Medicine.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  36. PIROFSKI LA
    Life as an Infectious Diseases Physician Scientist: Science is Humanity's Lifeline.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  37. DEL RIO C
    From Trained Infectious Diseases Clinician to Global Health Leader, Reflections on the Last 30 Years.
    J Infect Dis. 2017;216.
    PubMed     Text format    


  38. NOGUERA-JULIAN M, Edgil D, Harrigan PR, Sandstrom P, et al
    Next-Generation Human Immunodeficiency Virus Sequencing for Patient Management and Drug Resistance Surveillance.
    J Infect Dis. 2017 Sep 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  39. GODFREY C, Bobkova M, Boucher C, Ravasi G, et al
    Regional Challenges in the Prevention of Human Immunodeficiency Virus Drug Resistance.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  40. CHIKATA T, Murakoshi H, Koyanagi M, Honda K, et al
    Control of HIV-1 by an HLA-B*52:01-C*12:02 protective haplotype.
    J Infect Dis. 2017 Sep 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  41. MCLAREN PJ, Pulit SL, Gurdasani D, Bartha I, et al
    Evaluating the impact of functional genetic variation on HIV-1 control.
    J Infect Dis. 2017 Sep 9. doi: 10.1093.
    PubMed     Text format     Abstract available


  42. LIU Y, Gaisa MM, Wang X, Swartz TH, et al
    Immune Microenvironments of Anal Cancer Precursors Differ by HIV-serostatus, Affecting Ablation Outcomes.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  43. NING T, Wolfe A, Nie J, Huang W, et al
    Naturally Occurring Single Amino Acid Substitution in the L1 Major Capsid Protein of Human Papillomavirus Type 16: Alteration of Susceptibility to Antibody-Mediated Neutralization.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  44. AKE JA, Schuetz A, Pegu P, Wieczorek L, et al
    Safety and Immunogenicity of PENNVAX(R)-G DNA Prime Administered by Biojector(R) 2000 or CELLECTRA(R) Electroporation Device with Modified Vaccinia Ankara-CMDR Boost.
    J Infect Dis. 2017 Sep 2. doi: 10.1093.
    PubMed     Text format     Abstract available


  45. SMITH B
    Toward Understanding the When and Why of Human Immunodeficiency Virus-Associated Stroke.
    J Infect Dis. 2017;216:509-510.
    PubMed     Text format    


  46. BENJAMIN LA, Allain TJ, Mzinganjira H, Connor MD, et al
    The Role of Human Immunodeficiency Virus-Associated Vasculopathy in the Etiology of Stroke.
    J Infect Dis. 2017;216:545-553.
    PubMed     Text format     Abstract available


  47. MOLLAN KR, Tierney C, Hellwege JN, Eron JJ, et al
    Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.
    J Infect Dis. 2017;216:554-564.
    PubMed     Text format     Abstract available


    August 2017
  48. WEITZMANN MN, Vikulina T, Roser-Page S, Yamaguchi M, et al
    Homeostatic Expansion of CD4+ T-cells Promotes Cortical and Trabecular Bone Loss while CD8+ T-cells Induce Trabecular Bone Loss Only.
    J Infect Dis. 2017 Aug 25. doi: 10.1093.
    PubMed     Text format     Abstract available


  49. ASMUTH DM, Thompson CG, Chun TW, Ma ZM, et al
    Tissue Pharmacologic and Virologic Determinants of Duodenal and Rectal GALT Immune Reconstitution in HIV-infected Patients Initiating Antiretroviral Therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  50. BOEIJEN LL, Montanari NR, de Groen RA, van Oord GW, et al
    Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy.
    J Infect Dis. 2017 Aug 23. doi: 10.1093.
    PubMed     Text format     Abstract available


  51. DE POKOMANDY A, Kaufman E, de Castro C, Mayrand MH, et al
    The EVVA Cohort Study: Anal and Cervical Type-Specific Human Papillomavirus Prevalence, Persistence, and Cytologic Findings in Women Living With HIV.
    J Infect Dis. 2017;216:447-456.
    PubMed     Text format     Abstract available


  52. CRABTREE KL, Wojcicki JM, Minhas V, Kankasa C, et al
    Food and Drink Sharing in the Household are Associated with HHV-8 Seroconversion in a Cohort of Zambian Children.
    J Infect Dis. 2017 Aug 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  53. CLUTTER DS, Zhou S, Varghese V, Rhee SY, et al
    Prevalence of Drug-Resistant Minority Variants in Untreated HIV-1-Infected Individuals With and Those Without Transmitted Drug Resistance Detected by Sanger Sequencing.
    J Infect Dis. 2017;216:387-391.
    PubMed     Text format     Abstract available


  54. VAN LAARHOVEN A, Dian S, Ganiem AR, van Crevel R, et al
    Reply to Neeradi et al and Dhawan and Sankhyan.
    J Infect Dis. 2017;216:395-396.
    PubMed     Text format    


    July 2017
  55. HENRICH TJ, Hobbs KS, Hanhauser E, Scully E, et al
    Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy.
    J Infect Dis. 2017;216:254-262.
    PubMed     Text format     Abstract available


  56. MARTIN DH, Manhart LE, Workowski KA
    Mycoplasma genitalium From Basic Science to Public Health: Summary of the Results From a National Institute of Allergy and Infectious Disesases Technical Consultation and Consensus Recommendations for Future Research Priorities.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


  57. HORNER PJ, Martin DH
    Mycoplasma genitalium Infection in Men.
    J Infect Dis. 2017;216.
    PubMed     Text format     Abstract available


    June 2017
  58. DELAUGERRE C, Antoni G, Mahjoub N, Pialoux G, et al
    Assessment of HIV Screening Tests for Pre-Exposure Prophylaxis Programs.
    J Infect Dis. 2017 Jun 27. doi: 10.1093.
    PubMed     Text format     Abstract available


  59. SCHOEMAN JC, Moutloatse GP, Harms AC, Vreeken RJ, et al
    Fetal metabolic stress disrupts immune homeostasis and induces pro-inflammatory responses in HIV-1 and cART-exposed infants.
    J Infect Dis. 2017 Jun 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  60. GODFREY C, Thigpen MC, Crawford KW, Jean-Phillippe P, et al
    Global HIV Antiretroviral Drug Resistance: A Perspective and Report of a National Institute of Allergy and Infectious Diseases Consultation.
    J Infect Dis. 2017 Jun 17. doi: 10.1093.
    PubMed     Text format    


  61. KOPP JB
    Chronic Kidney Disease in the Aging Human Immunodeficiency Virus-Infected Population.
    J Infect Dis. 2017 Jun 13. doi: 10.1093.
    PubMed     Text format    


    May 2017
  62. HIRAKAWA H, Gatanaga H, Ochi H, Fukuda T, et al
    Antiretroviral therapy containing HIV protease inhibitors enhances fracture risk by impairing osteoblast differentiation and bone quality.
    J Infect Dis. 2017 May 19. doi: 10.1093.
    PubMed     Text format     Abstract available


  63. STEINAU M, Gorbach P, Gratzer B, Braxton J, et al
    Concordance between Anal and Oral Human Papillomavirus (HPV) Infections Among Young Men Who Have Sex with Men.
    J Infect Dis. 2017 May 15. doi: 10.1093.
    PubMed     Text format     Abstract available


  64. KEATING SM, Pilcher CD, Jain V, Lebedeva M, et al
    HIV Antibodies Detect HIV Persistence and Low Level Viral Replication.
    J Infect Dis. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


  65. LUO Z, Li Z, Martin L, Wan Z, et al
    Pathological role of anti-CD4 antibodies in HIV-infected immunologic non-responders under viral suppressive antiretroviral therapy.
    J Infect Dis. 2017 May 11. doi: 10.1093.
    PubMed     Text format     Abstract available


    April 2017
  66. GAY CL, Bosch RJ, Ritz J, Hataye JM, et al
    Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.
    J Infect Dis. 2017 Apr 18. doi: 10.1093.
    PubMed     Text format     Abstract available


  67. THUONG NTT, Heemskerk D, Tram TTB, Thao LTP, et al
    Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral Inflammation and Survival From Tuberculous Meningitis.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  68. VAN LAARHOVEN A, Dian S, Ruesen C, Hayati E, et al
    Clinical Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  69. CHOI JY, Pond SLK, Anderson CM, Richman DD, et al
    Molecular Features of the V1-V4 Coding Region of Sexually Transmitted HIV-1.
    J Infect Dis. 2017 Apr 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  70. SYPSA V, Psichogiou M, Paraskevis D, Nikolopoulos G, et al
    Rapid Decline in HIV Incidence Among Persons Who Inject Drugs During a Fast-Track Combination Prevention Program After an HIV Outbreak in Athens.
    J Infect Dis. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format     Abstract available


  71. CHAN PA, Flanigan TP
    Effective HIV Prevention Interventions and the Need for Rapid Mobilization to Address HIV Outbreaks Among At-Risk Populations.
    J Infect Dis. 2017 Apr 12. doi: 10.1093.
    PubMed     Text format    


  72. HERRERA BB, Chang CA, Hamel DJ, Mboup S, et al
    Continued transmission of Zika virus in humans in West Africa, 1992-2016.
    J Infect Dis. 2017 Apr 8. doi: 10.1093.
    PubMed     Text format     Abstract available


    March 2017
  73. VERMUND SH
    The Continuum of HIV Care in the Urban United States: Black Men Who Have Sex With Men (MSM) Are Less Likely Than White MSM to Receive Antiretroviral Therapy.
    J Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format    


  74. RAHIMY E, Li FY, Hagberg L, Fuchs D, et al
    Blood-Brain Barrier Disruption Is Initiated During Primary HIV Infection and Not Rapidly Altered by Antiretroviral Therapy.
    J Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  75. HOOTS BE, Finlayson TJ, Wejnert C, Paz-Bailey G, et al
    Updated Data on Linkage to Human Immunodeficiency Virus Care and Antiretroviral Treatment Among Men Who Have Sex With Men-20 Cities, United States.
    J Infect Dis. 2017 Mar 29. doi: 10.1093.
    PubMed     Text format     Abstract available


  76. DING Y, Lin H, Liu X, Wong FY, et al
    Higher Prevalence of Frailty Among a Sample of HIV-Infected Middle-aged and Older Chinese Adults Is Associated With Neurocognitive Impairment and Depressive Symptoms.
    J Infect Dis. 2017 Mar 16. doi: 10.1093.
    PubMed     Text format     Abstract available


  77. ERLANDSON KM, Wu K, Koletar SL, Kalayjian RC, et al
    Association Between Frailty and Components of the Frailty Phenotype With Modifiable Risk Factors and Antiretroviral Therapy.
    J Infect Dis. 2017;215:933-937.
    PubMed     Text format     Abstract available


  78. KHOURY G, Fromentin R, Solomon A, Hartogensis W, et al
    Human Immunodeficiency Virus Persistence and T-Cell Activation in Blood, Rectal, and Lymph Node Tissue in Human Immunodeficiency Virus-Infected Individuals Receiving Suppressive Antiretroviral Therapy.
    J Infect Dis. 2017;215:911-919.
    PubMed     Text format     Abstract available


  79. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017;215:928-932.
    PubMed     Text format     Abstract available


  80. MARGOT NA, Wong P, Kulkarni R, White K, et al
    Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
    J Infect Dis. 2017;215:920-927.
    PubMed     Text format     Abstract available


  81. CELUM C, Hong T, Cent A, Donnell D, et al
    Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study.
    J Infect Dis. 2017;215:907-910.
    PubMed     Text format     Abstract available


  82. BORITZ EA, Douek DC
    Perspectives on Human Immunodeficiency Virus (HIV) Cure: HIV Persistence in Tissue.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  83. RILEY JL, Montaner LJ
    Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  84. HENRICH TJ, Deeks SG, Pillai SK
    Measuring the Size of the Latent Human Immunodeficiency Virus Reservoir: The Present and Future of Evaluating Eradication Strategies.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  85. NIXON CC, Mavigner M, Silvestri G, Garcia JV, et al
    In Vivo Models of Human Immunodeficiency Virus Persistence and Cure Strategies.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  86. MULLINS JI, Frenkel LM
    Clonal Expansion of Human Immunodeficiency Virus-Infected Cells and Human Immunodeficiency Virus Persistence During Antiretroviral Therapy.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  87. MARGOLIS DM
    Towards an HIV Cure: a View of a Developing Field.
    J Infect Dis. 2017;215.
    PubMed     Text format    


  88. MARGOLIS DM, Archin NM
    Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  89. FERRARI G, Pollara J, Tomaras GD, Haynes BF, et al
    Humoral and Innate Antiviral Immunity as Tools to Clear Persistent HIV Infection.
    J Infect Dis. 2017;215.
    PubMed     Text format     Abstract available


  90. WYLES D, Saag M, Viani RM, Lalezari J, et al
    TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
    J Infect Dis. 2017 Mar 14. doi: 10.1093.
    PubMed     Text format     Abstract available


  91. LEE S, Byakwaga H, Boum Y, Burdo TH, et al
    Immunologic Pathways that Predict Mortality in HIV-Infected Ugandans Initiating ART.
    J Infect Dis. 2017 Mar 1. doi: 10.1093.
    PubMed     Text format     Abstract available


    February 2017
  92. TER KUILE FO, Taylor SM
    Gilding the lily?: Enhancing antenatal malaria prevention in HIV-infected women.
    J Infect Dis. 2017 Feb 28. doi: 10.1093.
    PubMed     Text format    


  93. NATUREEBA P, Kakuru A, Muhindo M, Littmann E, et al
    Intermittent Preventive Treatment with Dihydroartemisinin-piperaquine for the Prevention of Malaria among HIV-infected Pregnant Women.
    J Infect Dis. 2017 Feb 22. doi: 10.1093.
    PubMed     Text format     Abstract available


  94. PHILLIPS AN, Stover J, Cambiano V, Nakagawa F, et al
    Impact of HIV drug resistance on HIV/AIDS associated mortality, new infections and antiretroviral therapy program costs in sub-Saharan Africa.
    J Infect Dis. 2017 Feb 17. doi: 10.1093.
    PubMed     Text format     Abstract available


  95. LEVIS W
    Clofazimine mechanisms of action in Mycobacteria, HIV, and Cancer.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  96. HANNA DB, Lin J, Post WS, Hodis HN, et al
    Association of macrophage inflammation biomarkers with progression of subclinical carotid artery atherosclerosis in HIV-infected women and men.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  97. JANES HE, Cohen KW, Frahm N, De Rosa SC, et al
    Higher T cell responses induced by DNA/rAd5 HIV-1 preventive vaccine are associated with lower HIV-1 infection risk in an efficacy trial.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  98. FEINSTEIN MJ, Lloyd-Jones DM
    Macrophage inflammation and cardiovascular disease in HIV: Mechanistic Insights and Future Directions.
    J Infect Dis. 2017 Feb 12. doi: 10.1093.
    PubMed     Text format    


  99. DZANIBE S, Adrian PV, Mlacha SZ, Dangor Z, et al
    Reduced Transplacental Transfer of Group B Streptococcus Surface Protein Antibodies in HIV-infected Mother-Newborn Dyads.
    J Infect Dis. 2017 Feb 9. doi: 10.1093.
    PubMed     Text format    


  100. KHOURY G, Fromentin R, Solomon A, Hartogensis W, et al
    HIV persistence and T-cell activation in blood, rectal and lymph node tissue in HIV-infected individuals receiving suppressive ART.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  101. GARGANO JW, Unger ER, Liu G, Steinau M, et al
    Prevalence of Genital Human Papillomavirus in Males, United States, 2013-2014.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


  102. UPRETY P, Lindsey JC, Levin MJ, Rainwater-Lovett K, et al
    Inflammation and Immune Activation in Antiretroviral-Treated HIV-1-Infected African Infants and Rotavirus Vaccine Responses.
    J Infect Dis. 2017 Feb 7. doi: 10.1093.
    PubMed     Text format    


    January 2017
  103. MARGOT NA, Wong P, Kulkarni R, White K, et al
    Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse Transcriptase and Protease in Antiretroviral Treatment-Naive Patients do not Affect Response to Tenofovir Disoproxil Fumarate- or Tenofovir Alafenamide-Containing Regimens.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  104. CELUM C, Hong T, Cent A, Donnell D, et al
    HSV-2 acquisition among HIV-1 infected adults treated with tenofovir as part of combination antiretroviral therapy: Results from the ACTG A5175 PEARLS study.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  105. LOFGREN S, Hullsiek KH, Morawski BM, Nabeta HW, et al
    Differences in Immunologic Factors Among Patients Presenting with Altered Mental Status During Cryptococcal Meningitis.
    J Infect Dis. 2017 Jan 30. doi: 10.1093.
    PubMed     Text format     Abstract available


  106. LIN WW, Nelson A, Ryon JJ, Moss WJ, et al
    Plasma cytokines and chemokines in Zambian children with measles: innate responses and association with HIV-1 co-infection and in-hospital mortality.
    J Infect Dis. 2017 Jan 24. pii: jix012. doi: 10.1093.
    PubMed     Text format     Abstract available


  107. ZANNI MV, Toribio M, Wilks MQ, Lu MT, et al
    Application of a Novel CD206+ Macrophage-Specific Arterial Imaging Strategy in HIV.
    J Infect Dis. 2017 Jan 16. doi: 10.1093.
    PubMed     Text format    


  108. JANSSEN S, Schutz C, Ward AM, Huson MA, et al
    Hemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort Study.
    J Infect Dis. 2017;215:247-258.
    PubMed     Text format     Abstract available


  109. HOBBS CV, Anderson C, Neal J, Sahu T, et al
    Trimethoprim-Sulfamethoxazole Prophylaxis During Live Malaria Sporozoite Immunization Induces Long-Lived, Homologous, and Heterologous Protective Immunity Against Sporozoite Challenge.
    J Infect Dis. 2017;215:122-130.
    PubMed     Text format     Abstract available


  110. NYOMBAYIRE J, Anzala O, Gazzard B, Karita E, et al
    First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    J Infect Dis. 2017;215:95-104.
    PubMed     Text format     Abstract available


  111. OTTICHILO RK, Polyak CS, Guyah B, Singa B, et al
    Malaria Parasitemia and Parasite Density in Antiretroviral-Treated HIV-Infected Adults Following Discontinuation of Cotrimoxazole Prophylaxis.
    J Infect Dis. 2017;215:88-94.
    PubMed     Text format     Abstract available


    December 2016
  112. CHENG A, Chang SY, Sun HY, Tsai MS, et al
    Long-term durability of responses to 2 or 3 doses of hepatitis A vaccination in HIV-positive adults on antiretroviral therapy.
    J Infect Dis. 2016 Dec 23. pii: jiw605. doi: 10.1093.
    PubMed     Text format     Abstract available


  113. GRABOWSKI MK, Gravitt PE, Gray RH, Serwadda D, et al
    Trends and determinants of human papillomavirus concordance among HIV-positive and HIV-negative heterosexual couples in Rakai, Uganda.
    J Infect Dis. 2016 Dec 23. pii: jiw631. doi: 10.1093.
    PubMed     Text format     Abstract available


  114. EVANS C, Chasekwa B, Rukobo S, Govha M, et al
    CMV acquisition and inflammation in HIV-exposed uninfected Zimbabwean infants.
    J Infect Dis. 2016 Dec 23. pii: jiw630. doi: 10.1093.
    PubMed     Text format     Abstract available


  115. BIRSE KD, Romas LM, Guthrie BL, Nilsson P, et al
    Genital injury signatures and microbiome alterations associated with depot medroxyprogesterone acetate usage and intravaginal drying practices.
    J Infect Dis. 2016 Dec 23. pii: jiw590. doi: 10.1093.
    PubMed     Text format     Abstract available


  116. BALKUS JE, Srinivasan S, Anzala O, Kimani J, et al
    Impact of periodic presumptive treatment for bacterial vaginosis on the vaginal microbiome among women participating in the Preventing Vaginal Infections trial.
    J Infect Dis. 2016 Dec 22. pii: jiw622. doi: 10.1093.
    PubMed     Text format     Abstract available


  117. MESQUITA PM, Preston-Hurlburt P, Keller MJ, Vudattu N, et al
    Role of IL-32 in HIV Reactivation and its Link to HIV-HSV Coinfection.
    J Infect Dis. 2016 Dec 22. pii: jiw612. doi: 10.1093.
    PubMed     Text format     Abstract available


  118. BIALAS KM, Westreich D, Cisneros de la Rosa E, Nelson CS, et al
    Maternal Antibody Responses and Nonprimary Congenital Cytomegalovirus Infection of HIV-1-Exposed Infants.
    J Infect Dis. 2016;214:1916-1923.
    PubMed     Text format     Abstract available


  119. STEEGEN K, Bronze M, Papathanasopoulos MA, van Zyl G, et al
    Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa.
    J Infect Dis. 2016;214:1826-1830.
    PubMed     Text format     Abstract available


  120. MARAIS S, Lai RP, Wilkinson KA, Meintjes G, et al
    Inflammasome activation underlies central nervous system deterioration in HIV-associated tuberculosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  121. MCFARLAND EJ, Powell TM, Onyango-Makumbi C, Zhang W, et al
    Ontogeny of CD4+ T Lymphocytes with Phenotypic Susceptibility to HIV-1 during Exclusive and Non-Exclusive Breastfeeding in HIV-1-exposed Ugandan Infants.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  122. DZANIBE S, Adrian PV, Kimaro Mlacha SZ, Dangor Z, et al
    Reduced trans-placental transfer of group B Streptococcus surface protein antibodies in HIV-infected mother-newborn dyads.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  123. TSO FY, Sawyer A, Kwon EH, Mudenda V, et al
    Kaposi's sarcoma-associated herpesvirus infection of neurons in HIV positive patients.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  124. BRAUNSTEIN SL, Robertson MM, Myers J, Abraham B, et al
    Increase in CD4+ T-Cell Count at the Time of HIV Diagnosis and Antiretroviral Treatment Initiation Among Persons With HIV in New York City.
    J Infect Dis. 2016;214:1682-1686.
    PubMed     Text format     Abstract available


    November 2016
  125. ALTHOFF KN
    The Shifting Paradigm of Care for Adults Living With HIV: Smoking Cessation for Longer Life.
    J Infect Dis. 2016.
    PubMed     Text format    


  126. REDDY KP, Parker RA, Losina E, Baggett TP, et al
    Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  127. GULICK RM, Wilkin TJ, Chen YQ, Landovitz RJ, et al
    PHASE 2 STUDY OF THE SAFETY AND TOLERABILITY OF MARAVIROC-CONTAINING REGIMENS TO PREVENT HIV INFECTION IN MEN WHO HAVE SEX WITH MEN (MSM) (HPTN 069/ACTG A5305).
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  128. GUNTHARD HF, Scherrer AU
    HIV-1 Subtype C, Tenofovir, and the Relationship With Treatment Failure and Drug Resistance.
    J Infect Dis. 2016;214:1289-1291.
    PubMed     Text format    


    October 2016
  129. ERLANDSON KM, Ng D, Jacobson LP, Margolick JB, et al
    Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men with or at Risk for HIV.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  130. IMP BM, Rubin LH, Tien PC, Plankey MW, et al
    Monocyte Activation is Associated with Worse Cognitive Performance in Virologically Suppressed HIV-Infected Women.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  131. ANDERSON AM, Munoz-Moreno JA, McClernon D, Ellis RJ, et al
    Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  132. MUDD JC, Panigrahi S, Kyi B, Moon SH, et al
    Inflammatory function of CX3CR1+ CD8 T cells in treated HIV infection is modulated by platelet interactions.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  133. ECKARD AR, Meissner EG, Singh I, McComsey GA, et al
    Cardiovascular Disease, Statins, and HIV.
    J Infect Dis. 2016;214 Suppl 2:S83-92.
    PubMed     Text format     Abstract available


  134. KOETHE JR, Heimburger DC, PrayGod G, Filteau S, et al
    From Wasting to Obesity: The Contribution of Nutritional Status to Immune Activation in HIV Infection.
    J Infect Dis. 2016;214 Suppl 2:S75-82.
    PubMed     Text format     Abstract available


  135. GIANELLA S, Letendre S
    Cytomegalovirus and HIV: A Dangerous Pas de Deux.
    J Infect Dis. 2016;214 Suppl 2:S67-74.
    PubMed     Text format     Abstract available


  136. MUDD JC, Brenchley JM
    Gut Mucosal Barrier Dysfunction, Microbial Dysbiosis, and Their Role in HIV-1 Disease Progression.
    J Infect Dis. 2016;214 Suppl 2:S58-66.
    PubMed     Text format     Abstract available


  137. FREEMAN ML, Shive CL, Nguyen TP, Younes SA, et al
    Cytokines and T-Cell Homeostasis in HIV Infection.
    J Infect Dis. 2016;214 Suppl 2:S51-7.
    PubMed     Text format     Abstract available


  138. HUNT PW, Lee SA, Siedner MJ
    Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection.
    J Infect Dis. 2016;214 Suppl 2:S44-50.
    PubMed     Text format     Abstract available


  139. SIEG SF
    Persistent Inflammation in Treated HIV Disease.
    J Infect Dis. 2016;214 Suppl 2:S43.
    PubMed     Text format    


    September 2016
  140. KOOIJ KW, Wit FW, Booiman T, van der Valk M, et al
    Cigarette smoking and inflammation, monocyte activation and coagulation in HIV-infected individuals on antiretroviral therapy compared to uninfected individuals.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  141. EDEN A, Nilsson S, Hagberg L, Fuchs D, et al
    Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: a Longitudinal Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  142. WANG L, Wiener J, Bulterys M, Wei X, et al
    Hepatitis B Viral Load Response to two Antiviral Regimens (Tenofovir/Lamivudine vs Lamivudine) in HIV and HBV Co-Infected Pregnant Women in Guangxi, China: the Tenofovir in Pregnancy (TiP) Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  143. BUCHACZ K, Lau B, Jing Y, Bosch R, et al
    Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010.
    J Infect Dis. 2016;214:862-72.
    PubMed     Text format     Abstract available


  144. FURRER H
    Opportunistic Diseases During HIV Infection-Things Aren't What They Used to Be, or Are They?
    J Infect Dis. 2016;214:830-1.
    PubMed     Text format    


  145. PETERSON I, Bar-Zeev N, Kennedy N, Ho A, et al
    Respiratory virus-associated severe acute respiratory illness (SARI) and viral clustering in Malawian children in a setting with a high prevalence of HIV, malaria and malnutrition.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  146. POPESCU I, Drummond MB, Gama L, Lambert A, et al
    HIV Suppression Restores Lung Mucosal CD4+ T-Cell Viral Immunity and Resolves CD8+ Alveolitis in Patients at Risk for HIV-associated COPD.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    August 2016
  147. IMAZ A, Martinez-Picado J, Niubo J, Kashuba AD, et al
    HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Initiating a First Antiretroviral Regimen.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  148. COOMBS RW, Krieger JN
    Semen Remains the Way Forward to understand HIV-1 Transmission.
    J Infect Dis. 2016.
    PubMed     Text format    


  149. RODRIGO C, Eltahla AA, Bull RA, Grebely J, et al
    Historical trends in the hepatitis C virus epidemics in North America and Australia.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  150. GUTIERREZ J, Menshawy K, Goldman J, Dwork AJ, et al
    Metalloproteinases and brain arterial remodeling with and without HIV.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  151. SRINIVASA S, Burdo TH, Williams KC, Mitten EK, et al
    Effects of Sodium Restriction on Activation of the Renin-Angiotensin-Aldosterone System and Immune Indices in HIV.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  152. KOSTADINOVA L, Shive C, Judge C, Zebrowski E, et al
    During HCV and HCV-HIV infection elevated plasma Autotaxin is associated with LPA and markers of immune activation that normalize during IFN-free HCV therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  153. MOFENSON LM
    Early Infant HIV Diagnosis: How Early is Early Enough?
    J Infect Dis. 2016.
    PubMed     Text format    


  154. FRANCKE JA, Penazzato M, Hou T, Abrams EJ, et al
    Clinical impact and cost-effectiveness of early infant HIV diagnosis in South Africa: Test timing and frequency.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  155. WALTER ND, de Jong BC, Garcia BJ, Dolganov GM, et al
    Adaptation of M. tuberculosis to impaired host immunity in HIV-infected patients.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  156. REIMERS LL, Mehta SD, Massad LS, Burk RD, et al
    The Cervicovaginal Microbiota and Its Associations with Human Papillomavirus (HPV) Detection in HIV-Infected and HIV-Uninfected Women.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  157. MARKOWITZ M, Deren S, Cleland C, La Mar M, et al
    Chronic hepatitis C infection and the pro-inflammatory effects of injection drug use.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  158. KILIANSKI A, Nuzzo JB, Modjarrad K
    Reply to Lipsitch.
    J Infect Dis. 2016.
    PubMed     Text format    


  159. GONZALEZ OA, Sagar M
    Antibodies and acidic environment do not enhance HIV-1 transcytosis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  160. RYOM L, Lundgren JD, Ross M, Kirk O, et al
    Renal Impairment and Cardiovascular Disease in HIV-positive Individuals; The D:A:D Study.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  161. FIERER DS
    The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression of Hepatitis C-infected Patients.
    J Infect Dis. 2016.
    PubMed     Text format    


    July 2016
  162. MASSUD I, Mitchell J, Babusis D, Deyounks F, et al
    Chemoprophylaxis with oral emtricitabine and tenofovir alafenamide combination protects macaques from rectal SHIV infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  163. WALL KM, Kilembe W, Vwalika B, Ravindhran P, et al
    Hormonal contraceptive use among HIV-positive women and HIV transmission risk to male partners, Zambia, 1994-2012.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  164. DIEDRICH CR, O'Hern J, Gutierrez MG, Allie N, et al
    Relationship between HIV-1 co-infection, IL-10, and M. tuberculosis in human lymph node granulomas.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  165. CANADAY DH, Toossi Z
    Granulomatous responses in HIV/TB co-infection.
    J Infect Dis. 2016.
    PubMed     Text format    


  166. BAETEN JM
    Making an Impact With Preexposure Prophylaxis for Prevention of HIV Infection.
    J Infect Dis. 2016.
    PubMed     Text format    


  167. JENNESS SM, Goodreau SM, Rosenberg E, Beylerian EN, et al
    Impact of the Centers for Disease Control's HIV Preexposure Prophylaxis Guidelines for Men Who Have Sex With Men in the United States.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  168. BOENDER TS, Hamers RL, Ondoa P, Wellington M, et al
    Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    June 2016
  169. DERUAZ M, Moldt B, Le KM, Power KA, et al
    Protection of Humanized Mice From Repeated Intravaginal HIV Challenge by Passive Immunization: A Model for Studying the Efficacy of Neutralizing Antibodies In Vivo.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  170. HUNT PW
    sCD163 and Clinical Outcomes in Treated HIV: Insights into Mechanisms.
    J Infect Dis. 2016.
    PubMed     Text format    


  171. KELESIDIS T, Moser C, Stein JH, Brown TT, et al
    Changes in markers of T cell senescence and exhaustion with Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  172. KNUDSEN TB, Ertner G, Petersen J, Moller HJ, et al
    Plasma CD163 independently predicts all-cause mortality from HIV-1 infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  173. GRANT PM, Kitch D, McComsey GA, Collier AC, et al
    Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  174. MEITES E, Gorbach PM, Gratzer B, Panicker G, et al
    Monitoring for HPV Vaccine Impact among Gay, Bisexual and other Men who have Sex with Men - United States, 2012-2014.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  175. CHEN YI MEI SL, Burchell J, Skinner N, Millen R, et al
    Toll-like receptor expression and signalling in peripheral blood mononuclear cells correlate with clinical outcomes in acute hepatitis C infection.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


    May 2016
  176. LAPRISE JF, Markowitz LE, Chesson HW, Drolet M, et al
    COMPARING 2- AND 3-DOSE 9-VALENT HPV VACCINE SCHEDULES IN THE U.S.: A COST-EFFECTIVENESS ANALYSIS.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  177. WHITE E, Smit E, Churchill D, Collins S, et al
    No Evidence That HIV-1 Subtype C Infection Compromises the Efficacy of Tenofovir-Containing Regimens: Cohort Study in the United Kingdom.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  178. SHILAIH M, Marzel A, Scherrer AU, Braun DL, et al
    Dually Active HIV/HBV Antiretrovirals Protect Against Incident Hepatitis B Infections: Potential for Prophylaxis.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


  179. PRENDERGAST AJ, Szubert AJ, Berejena C, Pimundu G, et al
    Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.
    J Infect Dis. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO HIV Infection is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: